Tags

Type your tag names separated by a space and hit enter

[Pharmacotherapy in the treatment of obesity].
MMW Fortschr Med. 2006 Mar 02; 148(9):36-8.MF

Abstract

Currently, the substances orlistat and sibutramine are approved drugs for the pharmacotherapy of obesity. Used in combination with increased exercise and dietary measures, both are capable of significantly reducing weight. In the USA and Europe, official approval for the selective cannabinoid receptor antagonist, rimonabant has been applied for.

Authors+Show Affiliations

Hamann A
Diabetes-Klinik Bad Nauheim und Abtei- lung Innere Medizin I, Universitätsklinikum Heidelberg. a.hamann.diabetes@pitzer-kliniken.de

MeSH

Anti-Obesity AgentsAppetite DepressantsCannabinoid Receptor AntagonistsClinical Trials as TopicCyclobutanesEnzyme InhibitorsExerciseHumansLactonesLipaseObesityOrlistatPiperidinesPyrazolesRimonabantTime FactorsWeight Loss

Pub Type(s)

Journal Article
Review

Language

ger

PubMed ID

16566392

Citation

Hamann, Andreas. "[Pharmacotherapy in the Treatment of Obesity]." MMW Fortschritte Der Medizin, vol. 148, no. 9, 2006, pp. 36-8.
Hamann A. [Pharmacotherapy in the treatment of obesity]. MMW Fortschr Med. 2006;148(9):36-8.
Hamann, A. (2006). [Pharmacotherapy in the treatment of obesity]. MMW Fortschritte Der Medizin, 148(9), 36-8.
Hamann A. [Pharmacotherapy in the Treatment of Obesity]. MMW Fortschr Med. 2006 Mar 2;148(9):36-8. PubMed PMID: 16566392.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Pharmacotherapy in the treatment of obesity]. A1 - Hamann,Andreas, PY - 2006/3/29/pubmed PY - 2006/5/6/medline PY - 2006/3/29/entrez SP - 36 EP - 8 JF - MMW Fortschritte der Medizin JO - MMW Fortschr Med VL - 148 IS - 9 N2 - Currently, the substances orlistat and sibutramine are approved drugs for the pharmacotherapy of obesity. Used in combination with increased exercise and dietary measures, both are capable of significantly reducing weight. In the USA and Europe, official approval for the selective cannabinoid receptor antagonist, rimonabant has been applied for. SN - 1438-3276 UR - https://www.unboundmedicine.com/medline/citation/16566392/[Pharmacotherapy_in_the_treatment_of_obesity]_ L2 - http://www.diseaseinfosearch.org/result/9028 DB - PRIME DP - Unbound Medicine ER -